LCTX
Lineage Cell Therapeutics, Inc.
A clinical-stage biotechnology company developing "off-the-shelf" cell therapies for serious conditions, including spinal cord injuries and age-related macular degeneration. It began in 1990 as BioTime before rebranding in 2019 to its current name, which reflects how its platform steers stem cells along specific "lineages" to become particular cell types. Its programs include OPC1 for spinal cord repair and OpRegen for the eye disease dry AMD.
WARRANTUnderlying: LCTXCUSIP: 09066L1621 holder
Common Share Purchase Warrants expiring October 1, 2018, exercise price .55